Patents by Inventor Achim Jungbluth

Achim Jungbluth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7521543
    Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
    Type: Grant
    Filed: October 23, 2003
    Date of Patent: April 21, 2009
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Cynthia Scanlan, legal representative, Gerd Ritter, Lloyd Old, Achim Jungbluth, Matthew Scanlan
  • Publication number: 20060292154
    Abstract: Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.
    Type: Application
    Filed: October 23, 2003
    Publication date: December 28, 2006
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Matthew Scanlan, Cynthia Scanlan, Gerd Ritter, Lloyd Old, Achim Jungbluth
  • Patent number: 6652853
    Abstract: This invention relates to a combination of immunotherapy and chemotherapy to promote tumor regression by treating a patient in need thereof with a combination of a humanized antibody that binds to A33 antigen and one or more chemotherapeutic agents. The method is useful for treating patients with colorectal cancer and gastric carcinomas. The method is particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: November 25, 2003
    Assignees: Ludwig Institute for Cancer Research, Sloan Kettering Institute for Cancer Research
    Inventors: Sydney Welt, Nancy Kemeny, Gerd Ritter, Achim A. Jungbluth, Leonard Cohen, Lloyd J. Old
  • Publication number: 20020187144
    Abstract: This invention relates to a combination of immunotherapy and chemotherapy to promote tumor regression by treating a patient in need thereof with a combination of a humanized antibody that binds to A33 antigen and one or more chemotherapeutic agents. The method is useful for treating patients with colorectal cancer and gastric carcinomas. The method is particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
    Type: Application
    Filed: March 8, 2001
    Publication date: December 12, 2002
    Inventors: Sydney Welt, Nancy Kemeny, Gerd Ritter, Achim A. Jungbluth, Leonard Cohen, Lloyd J. Old
  • Patent number: 5674749
    Abstract: The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule Melan-A, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of Melan-A and immunogenic compositions containing the molecules, and an adjuvant.
    Type: Grant
    Filed: March 26, 1996
    Date of Patent: October 7, 1997
    Assignees: Ludwig Institute For Cancer Research, Memorial Sloan Kettering Cancer Center, Cornell Research Foundation, Inc.
    Inventors: Yao-tseng Chen, Elisabeth Stockert, Achim Jungbluth, Lloyd J. Old